Drug Shortage Report for SODIUM ACETATE INJECTION, USP
Report ID | 131721 |
Drug Identification Number | 02139529 |
Brand name | SODIUM ACETATE INJECTION, USP |
Common or Proper name | Sodium Acetate Injection, USP 4 mEq/mL Maxivial® 100 mL |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | SODIUM ACETATE |
Strength(s) | 328MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 100 mL |
ATC code | B05XA |
ATC description | I.V. SOLUTION ADDITIVES |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2021-01-06 |
Actual start date | |
Estimated end date | Unknown |
Actual end date | 2021-02-09 |
Shortage status | Resolved |
Updated date | 2021-02-10 |
Company comments | Fresenius Kabi Canada Ltd. is pleased to advise that our Sodium Acetate Injection will be removed off allocation effective today, Tuesday, February 9, 2021. The product will be available to all customers without restrictions. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v7 | 2021-02-10 | English | Compare |
v6 | 2021-02-09 | French | Compare |
v5 | 2021-02-09 | English | Compare |
v4 | 2021-01-15 | French | Compare |
v3 | 2021-01-15 | English | Compare |
v2 | 2021-01-15 | French | Compare |
v1 | 2021-01-15 | English | Compare |
Showing 1 to 7 of 7